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                           INTRODUCTION 
  
 
Multiple myeloma is a monoclonal plasma cell neoplasm 
resulting in lytic lesions of the bones and paraproteinemia leading 
to renal failure, pathological fractures , infections, hyper viscosity 
syndromes etc. Its the commonest primary bone malignancy in the 
western world. Every year, almost 15,000 new cases of myeloma 
are reported in united States(1) compared to the less than 1000 
cases reported in India.(2). According to the western data Myeloma 
is primarily a disease of the elderly with only 18% of the cases 
reported below 60 years. The median survival is 3 years. Therapy 
and prognostic factors have been constant source of inspiration for 
research , as a result we have paradigm of therapeutic modalities. 
Most of the data regarding myeloma is from the foreign literature, 
this study is an attempt to analyse the pattern of presentation of  
Myeloma at Madurai Govt  Rajaji Hospital which primarily caters 
to the rural population in and around Madurai. 
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REVIEW OF LITERATURE 
DEFINITION : 
                      Multiple myeloma / kahler’s disease is a malignant 
monoclonal  proliferation of the plasma cells. Its also known as 
plasma cell myeloma, Myelomatosis. 
HISTORY : 
                    November 1st 1845 Saturday .: Dr.William McIntyre, 
a leading  consultant physician at London sends a urine sample to 
Dr.Henry bence Jones , with the following Quote  
Dear Dr.Jones,  
            “The tube contains urine of very high specific gravity 
when boiled it becomes slightly opaque. On the addition of nitric 
acid it effervesces it assumes a reddish hue and becomes quite 
clear but as it cools assumes the consistency and appearence which 
you see. Heat  liquefies it . what is it?(4)” 
The urine belonged to Mr.Thomas Alexander McBean who 
complained of progressive pain in the chest, back and loin since 
one year.Dr.Jones, demonstrated the heat coagulation properties of 
the urine proteins, now is well know as the bence jones proteins of 
multiple myeloma. The autopsy of Mr.Mc Bean, revealed soft and 
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brittle ribs, sternum and vertebrae, filled with gelatinous material, 
which on microscopic examination revealed large round uni or bi 
nucleated cells  which resembled the myeloma cells.The name 
“mollitis ossium” was given to this queer disease.                  
The term multiple myeloma was introduced in 1873 by J.Von 
Rustizky, but the classic illustration of Multiple Myeloma, was 
given by Dr.otto Kahler in 1889, who described the disease in a 
fellow  Physcian. Dr.Otto Kahler was the first one togive a 
detailed description  of multiple myeloma, hence the disease is 
also known as “ Kahler’s Disease” in his honour. Wright was the 
first one to point out that myeloma cells are nothing but plasma 
cells, by 1917 it was demonstrated that bence jones protein were 
elevated both in urine and serum,  In 1939, myeloma serum 
globulins were separated by electrophoresis and M component was 
described. Dr.Mcintyre question was finally answered when 
korngold and Lipari showed similarities between the urine 
bencejones proteins and the light chains prepared from both 
myeloma and normal patients. In their honour the light chains are 
named as kappa and lambda. 
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EPIDEMIOLOGY:  
The incidence of multiple myeloma is lowest in the  south 
asian  and middle east countries. Every year 15000 new cases of 
multiple myeloma are reported , 11000 deaths are due to myeloma 
in the united States, incidence being 3/100000, while in India 2003 
-2004, the cumulative risk was caluculated to be 0.18/100000, can 
be blamed partially on faulty reporting. However the incidence of 
multiple myeloma is highest among the blacks followed by Maoris, 
Hawaiian , Israeli jews, north Europeans, US and Canadian 
whites.The incidence of myeloma is much lower even in our other 
south Asian countries like China and Japan. Its noted that the 
incidence of Multiple Myeloma is increasing among American 
Indians in past decade but is definetly nowhere near their native 
American counter parts. 
AGE  -  Multiple myeloma is predominatly a disease of the 
elderly, the mean age of incidence being 68yrs. 
SEX PREDILECTION – Males are slightly more affected than 
males. 
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AETIOLOGY  
 The cause of multiple myeloma is not clear. 
Environmental exposure : 
         The strongest environmental link to the cause of multiple 
myeloma is ionizing radiation, 29 people among the Nagasaki 
bomb survivors died out of multiple myeloma. However some 
recent studies donot confirm the increased risk of multiple 
myeloma among these people. However the role of pesticides, 
chemicals, benzene, smoking 
 is supported by only epidemiological studies and there is no 
strong scientific evidence till date.  
Genetic predisposition : 
         The direct genetic  link for multiple myeloma is not 
established, however the racial and gender  predilection proposes 
an genetic component to the etiology. In the large scale 
multicentric study done by the Mayoclinic , 8 siblings had the 
disease , in an Sweden based study of multiple myeloma, the 
relative risk of inheritance in  males was 3.86 if the father had 
Multiple myeloma. Moreover substantial family clustering was 
found in many cases. There is significant association of HLACw2 
and HLA Cw5  to Multiple myeloma. 
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Chronic Antigen stimulation :  
Many M proteins have been shown to be antibodies against 
specific antigens, such as microbiological antigens, RBC antigens, 
neural antigens, lipoproteins, rheumatoid factors and coagulation 
factors. Chronic antigenic stimulation may predispose to the 
development of multiple myeloma as in cases of chronic 
osteomyelitis and cholecystitis.A recent case controlled study 
suggested that females with silicon transplants have a higher risk 
for developing multiple myeloma. 
 
Virus : 
            Human herpes virus 8 has been found in the nonmalignant 
marrow dendritic bone cells of patients with multiple myeloma. Its 
still not proven that they play a role in the malignant 
transformation of multiple myeloma. 
CYTOGENETICS 
            The malignant plasma cells carry complex chromosomal 
abnormalities that increase with disease progression. Microarray 
analysis has shed more light on sequential genetic changes from 
normal cells to myeloma cells and the multi step progression from 
from MGUS to multiple myeloma. Recent advances in cytogenetics 
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have showed that IgH translocations and aneuploidy  states could 
be the possible early signatures of multiple myeloma. The common 
translocations include, t(11;14), t(14;16), t(4;14), t(6;14).these 
translocations, these IgH translocations are mediated by the VDJ 
recombination errors. These translocations may increase in 
frequency as the disease. progresses and result in activation of 
cyclin D1, D2, D3 or myeloma set domains or fibroblast growth 
factor 3 genes. These changes would trigger of the initial 
malignant proliferation and help in  survival of the malignant  
plasma cells. However the disease progression is sustained by 
further chromosomal abnormalities, like P53 mutation, cmyc and 
ras gene mutation. Probably these bizarre multiple genetic 
abnormalities makes multiple myeloma still an incurable 
disease.Chromosome 13 translocations, P53 deletions, cmyc 
mutation are associated with poor prognosis.Thus genetic analysis 
is not needed for diagnosis but definetly plays a role in assessing 
the prognosis. 
PATHOGENESIS:  
Initially cell production from the bone marrow stem cell results in 
two  lineages with lymphoid characteristics : pre- T cell and pre-B 
cell. The first will migrate to the Thymus where they will be 
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differentiated  into T cells. The last cells will reach the peripheral 
blood as " tracer  lymphocytes " . This kind of cell is the result of 
a process of  differentiation not related to antigen that produces a 
great variety  of cells which express small amounts of 
immunoglobulin on their surface. These cells, at some moment of 
their lives, will be stimulated by antigens  or cytokines from 
helper T cells and will migrate to lymph nodes where  they initiate 
a clonal proliferation which results in plasmablasts that  express 
on their surface IgM and IgA. Those cells can go in two ways:  get 
back to the blood as helper T cells or migrate to the bone marrow. After the 
activated B cells enter the bone marrow, they stop proliferating and differentiate 
into plasma cells, under the influence of adhesion molecules and factors such 
interleukin-6. They start to produce immunoglobulin and die by apoptosis after 
several weeks or months. What initiates this process is still unclear. The cells in 
Multiple Myeloma are often immature, may have the appearance of 
plasmablasts and produce low amounts of clonal immunoglobulin. The cause of 
the failure in the process of differentiation is not clear, but chromosomal 
translocation and increase in the expression of oncogen Cmyc could play an 
important role.The rate of cell proliferation in the beginning of Multiple 
Myeloma disease is very low compared to the terminal phase. The myeloma 
cells are aneuploid and their chromosomes have many numerical and structural 
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abnormalites that seems to prevent the differentiation and death of these cells, 
which continue to proliferate and accumulate in the bone marrow. All these 
alterations are correlated with resistance to treatment and short survival 
characteristc of aggressive disease.Interleukin 6 plays a very important role in 
the proliferation of myeloma cells. Its not just Proliferative factor but also an 
survival factor. Interleukin-6 is essential for the survival and growth of 
myeloma cells, which express specific receptors for this cytokine, and also 
prevents spontaneously by bone cells and stromal cells after 
stimulation by myeloma cells. It exerts its effect by triggering 
atleast two intercellular cascades, JAKSTAT  and RAS/MAPK  
pathways. Cytokines like Insulin like growth factor 1, vascular 
endothelial growth factor, tumuor necrosis factor alpha, 
transforming growth factor beta, IL 10 and stromal cell derived 
factor 1 alpha also play an important role in the proliferation and 
survival of myeloma cells dexamethasone induced apoptosis. 
PATHOGENESIS OF BONE LESIONS 
The  development  of bone  lesions in MM is caused by an imbalance 
between the activity of osteoclasts and osteoblasts. There is an increase in 
RANKL (receptor activator of  nuclear factor B ligand) expression by 
osteoblasts (and possibly plasma cells) accompanied by a reduction in the level  
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of its decoy receptor, osteoprotegerin (OPG). This leads to an increase in 
RANKL/OPG ratio, which causes osteoclast activation and  bone resorption. In 
addition, increased levels of macrophage inflammatory protein–1  (MIP-1 ), 
interleukin (IL)-3 and IL-6 produced by marrow stromal cells contribute to the 
overactivity of osteoclasts. At the same time, increased levels of IL-3, IL-7 and   
DKK1 produced by marrow stroma inhibit osteoblast Different 
-iation.. These changes lead to osteoclast activation and bone  
resorption without any repair activity by  osteoblasts. 
CLINICAL MANIFESTATIONS OF MULTIPLE MYELOMA 
Multiple myeloma is usually asymptomatic in early stages. 
The symptoms in myeloma could be due to the disease activity or 
due to the complication. The Presenting symptoms  could range 
from just back ache, to pathologic fractures, paraperesis , dyspnoea 
severe pallor, infection, seizure, stupor, coma……Increasingly, 
physicians are identifying asymptomatic patients through routine 
blood screening.  
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SKELETAL DISEASE IN MULTIPLE MYELOMA: 
1.Back Ache  -   is the most common presenting symptom. Most series report 
that 70% of patients have back ache at presentation. Backache  is 
predominantly bone pain due to the lytic lesion  of the vertebra. The lumbar 
vertebrae are one of the most common sites  of pain.  
2 other bone  Pain – depending on the skeletal involvement involved, patients 
can present With varying aches and pains localized to respective structures. 
93% of patients have  more than one bony  involvement. 
3.pathological fracture  
DEFECTIVE HEMATOPOIESIS 
1.Anemia : can present with easy fatigability, weakness and dyspnoea .60% of 
the  Patients at the time of diagnosis have anemia. 
2.bleeding : Occasionally a patient may come to medical attention for bleeding 
resulting  from thrombocytopenia.!5% of patients at the tim of diagnosis have 
thrombocytopenia.  In some patients, monoclonal protein may absorb clotting 
factors and lead to bleeding,  but this development is rare.  
3.Infection :Abnormal humoral immunity and leukopenia may lead to 
infection.  Pneumococcal organisms are commonly involved, but shingles (ie, 
herpes zoster) and Haemophilus infections are also more common among 
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patients with myeloma. Leukopenia is present in 15% of patients at the time of 
diagnosis. 
RENAL DYSFUNCTION  
           Acute and chronic renal failure is a part of multiplemyeloma , the 
incidence being 15 – 20%, presenting with uraemic symptoms like nausea, 
vomiting , hiccoughs,  Decreased urine out put, altered sensorium with flapping 
tremors, signs of fluid overload.Renal dysfunction in multiple myeloma could 
be due to Myeloma kidney, as a result of precipitation light chains in the 
tubules , leading to obstruction, inflammation and scarring,.can thus present as 
fanconi’s syndrome. Even glomerular sclerosis ia part of myeloma kidney. The 
other causes of renal involvement in myeloma is secondary to hypercalcemia  
and Amyloidosis. 
NEUROLOGICAL DYSFUNCTION : 
1.Spinal cord compression : symptoms of  spinal cord compression are back 
pain,  root  pain, band like sensation,  weakness, numbness, or dysesthesias in 
the extremities.  Patients who are ambulatory at the start of therapy have the 
best likelihood of preserving function and avoiding paralysis. This complication 
occurs in approximately 10-20% of patients at some time during the course of 
disease. 
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2.Space occupying lesion in brain – very raely meningeal plasmacytomas, 
cerebral plasmacytomas can present with seizures and features of raised 
intracranial tension. 
3. Meningitis – secondary to infections especially streptococcus pneumoniae. 
4. Peripheral neuropathy - Carpal tunnel syndrome is a common complication 
of  myeloma.. Some peripheral neuropathies have been attributed to myeloma 
Metabolic abnormalities - 
1.Hypercalcemia : symptoms include  confusion, somnolence, bone pain, 
constipation,  nausea, and thirst. This complication may be present in as many 
as 30% of patients at  presentation. In most solid malignancies, this carries an 
ominous prognosis, but in  myeloma, its occurrence does not adversely affect 
survival. 
2.Hyponatremia, Hypokalemia and Metabolic alkalosis – secondary 
to fanconi’s syndrome. 
Hyperviscosity - Due to hyperimmunoglobulinemia. Epistaxis may be a 
presenting symptom of myeloma with a high tumor volume. Occasionally, 
patients may have such a high volume of monoclonal protein that  their blood 
viscosity increases, resulting in complications such as stroke, myocardial  
ischemia, or infarction. Patients may report headaches and somnolence, and 
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they may  bruise easily and have hazy vision. Patients typically experience 
these symptoms when  their serum viscosity is greater than 4 times that of 
normal serum. 
Physical examination 
• Patients may  have  pallor  resulting  from  anemia. 
• Patients may have ecchymoses or purpura resulting from 
thrombocytopenia. 
• Bony tenderness is not uncommon, resulting from focal lytic destructive 
bone lesions or pathologic fracture. Pain without tenderness is typical. 
• spinomotor system examination  may reveal features of compressive 
myelopathy with definite sensory and motor level , there could also be 
multiple levels of compression 
• .Extramedullary plasmacytomas, which consist of soft tissue masses of 
plasma cells, are not uncommon. Plasmacytomas have been described in 
almost every site in the body. Although the aerodigestive tract is the 
most common location,reports also describe orbital, ear canal, cutaneous, 
gastric, rectal, prostatic, and  retroperitoneal  
•  hepatomegaly and splenomegaly  
 
 15
PHYSICAL FINDINGS IN AMYLOIDOSIS              
A.The shoulder pad sign is defined by bilateral swelling of the 
shoulder joints secondary to amyloid deposition. Physicians 
describe the  swelling as hard and rubbery. Amyloidosis may also 
be associated with  carpal tunnel syndrome and subcutaneous 
nodules.  
B Macroglossia is a common finding in patients with amyloidosis.  
C. Skin lesions that have been described as wax papules or nodules 
may occur on the torso, ears, or lips.  
D. Postprotoscopic peripalpebral purpura strongly suggests 
amyloidosis. Patients may develop raccoonlike dark circles around 
their eyes following  
anyprocedure that parallels a prolonged Valsalva maneuver. The 
capillary fragility associated with amyloidosis may account for this 
observation. The correlation was observed when patients in the 
past underwent rectal biopsies  to  make  the  diagnosis. 
 
 
 
 16
WORK UP   
 
The standard evaluation of a patient with suspected myeloma includes:  
1) complete hemogram  including erythrocyte sedimentation rate. 
2) Blood chemistry profile including calcium, urea, creatinine, LDH, 
albumin,  uric Acid, serum electrolytes, total proteins , serum albumin.  
3) Serum beta-2 microglobulin and Lactate dehydrogenase 
may be a mesure of tumour burden especially the former. 
4) Creactive protein - a surrogate marker for IL-6  
5)  Bone marrow aspirate and biopsy with cytogenetics and 
plasma cell labeling index  
6) Complete skeletal survey – Xray of  skull and long bones is 
required in all cases of multiple myeloma. MRI may be 
required in the case of paraspinal mass, features of 
compressive myelopathy, radiculopathy. Bone scans are of 
limited use, PET scans are rarely used to evaluate the 
extent of the disease. Bone densitometry is useful in 
followup of multiple myeloma , as it helps in predicting the 
risk of fractures and casn also help in assessing the 
response to bisphosphonates.  
7)  7.light chains in urine - A routine urinalysis will not detect 
Bence Jones proteins. There are several methods used by 
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laboratories to detect and measure these proteins. The 
classic Bence Jones reaction involves heating urine to 
140&deg;F (60&deg;C). At this temperature, the Bence 
Jones proteins will clump. The clumping disappears if the 
urine is further heated to boiling and reappears when the 
urine is cooled. Other clumping procedures using salts, 
acids, and other chemicals are also used to detect these 
proteins. These types of test will reveal whether or not 
Bence Jones proteins are present, but not how much is 
present. This test is highly unreliable. The best method 
would be to do a Urine protein electrophoresis and 
immunofixation in 24 hour urine sample. Urine 
electrophoresis shows a globulin spike in 75% of patients.  
8) Serum protein electrophoresis  and  immunofixation :  To 
identify     M protein   And quantification of it.  Serum 
protein electrophoresis (SPEP) shows a monoclonal spike in 
85% of multiple myeloma patients.  
Urine electrophoresis shows a globulin spike in 75% of 
patients.  Sixty percent of the patients have a monoclonal protein 
that is immunoglobulin G (IgG), 20 % IgA, 1% IgD or non-
secretory, and 15% are light chain only.  
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DIAGNOSIS OF MULTIPLE MYELOMA 
Major criteria – 
1.I = Plasmacytoma on tissue biopsy  
2.II = Bone marrow with greater than 30% plasma cells  
3.III = Monoclonal globulin spike on serum protein 
electrophoresis, with an immunoglobulin G (IgG) peak of greater 
than 3.5 g/dL or an immunoglobulin A (IgA) peak of greater than 2 
g/dL, or urine protein electrophoresis (in the presence of 
amyloidosis) result of greater than 1 g/24 h. 
 Minor criteria - 
a = Bone marrow with 10-30% plasma cells  
b = Monoclonal globulin spike present but less than category III  
c = Lytic bone lesions  
d = Residual normal immunoglobulin M (IgM) level of less than 50  
mg/dL, IgA level of less than 100 mg/dL, or IgG level of less than 
 600 mg/dL 
The following combinations of findings are used to make the 
diagnosis: 
I plus b 
I plus c 
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I plus d 
II plus b  
II plus c  
II plus d 
III plus a  
III plus c  
III plus d  
a plus b plus c or a plus b plus d 
 
 
Classification of Myeloma 
 
Patients may be classified into one of three myeloma 
categories (MGUS,Asymptomatic, and Symptomatic) to help to 
determine treatment options. Patients in some categories do not 
have to receive treatment immediately, but may receive 
bisphosphonates if osteoporosis is present, or other supportive care 
for symptomsand complications. In these cases, postponing therapy 
may help avoid unnecessary side effects and the risk of 
complications associated with chemotherapy and may also delay 
development of resistance to chemotherapy 
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Monoclonal Gammopathy of Undetermined Significance 
(MGUS) 
MGUS is a common condition where a monoclonal protein is 
present. However, there are no symptoms, other criteria for 
myeloma diagnosis are absent, and no cause for the increased 
protein can be identified. MGUS occurs in about 1%of the general 
population and in about 3% of normal individuals over 70 years of 
age. MGUS itself is harmless but over many years approximately 
16% of individuals with MGUS will progress to a malignant 
plasma cell disorder. Characteristics: 
  Serum M protein <3 g/dL 
  Bone marrow plasma cells <10% 
          Absence of anemia, renal failure, hypercalcemia, lytic bone 
lesions. 
Asymptomatic Multiple Myeloma Patients with asymptomatic 
multiple myeloma have a monoclonal protein and slightly 
increased numbers of plasma cells in the bone marrow. They may 
have mild anemia and/or a few bone lesions, but do not exhibit the 
renal failure and frequent infections that characterize active 
multiple myeloma. In these patients the myeloma is static and may 
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not progress for months or years. Asymptomatic multiple myeloma 
includes both Smoldering Multiple Myeloma (SMM) and Indolent 
Multiple Myeloma (IMM).  
  Smoldering Multiple Myeloma (SMM) 
  Characteristics 
  Serum M protein >3 g/dL and/or bone marrow 
plasma cells ≥10% 
  Absence of anemia, renal failure, hypercalcemia, 
lytic bone lesions 
     Indolent Multiple Myeloma (IMM) Characteristics 
  Stable serum/urine M protein 
  Bone marrow plasmacytosis 
  Mild anemia or few small lytic bone lesions 
  Absence of symptoms. 
Symptomatic Multiple Myeloma (MM) 
Characteristics 
  1.Presence of serum/urine M protein 
  2.Bone marrow plasmacytosis (>30%) 
  3.Anemia, renal failure, hypercalcemia, or lytic bone lesions 
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Staging of Myeloma 
The process of staging myeloma is crucial to developing an 
effective treatment plan. The staging system most widely used 
since 1975 has been the Durie-Salmon system, in which clinical 
stage of disease (stage I, II, or III) is based on four measurements: 
levels of M protein, the number of lytic bone lesions, hemoglobin 
values (a measure of the number of red blood cells in the blood), 
and serum calcium levels. Stages are further divided according to 
renal (kidney) function (classified as A or B; Table 3).  
There is somewhat of an overlap between the various myeloma 
categories and stages. For example, both patients with smoldering 
myeloma and patients with Stage I disease do not require 
immediate treatment, and patients with Stage II and III disease 
have active, symptomatic myeloma. Increasingly, physicians are 
relying less on the Durie-Salmon staging system and more on 
biologically relevant markers as prognostic indicators when 
making treatment choices. 
A new, simpler, more cost-effective alternative is the 
International Staging System (ISS). The ISS is based on the 
assessment of two blood test results, beta 2-microglobulin (β2-M) 
and albumin, which together showed the greatest prognostic power 
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for multiple myeloma. This system has only recently been 
developed, but has already been proven more sensitive in 
discriminating between three stages of the disease, which indicate 
different levels of projected survival and suggest increasingly 
more aggressive treatment strategies. This system is based on the 
level of beta 2 microglobulin, which is a very good indicator of 
tumour burden. Several studies done correlating beta2 
microglobulin and plasmacell labelling index, have proved that 
beta 2 microglobulin directly correlates with the plasma cell 
labelling index , further studies have shown that beta 2 
microglobulin  is a very good prognostic marker, beta2 
microglobulin level  > 3.5g/dl  have  indicated poor prognosis and 
high five year mortality. Serum albumin also is a prognostic 
indicator, studies have shown lower is the serum albumin worser is 
the survival rate . 
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The following table summarizes the staging criteria. 
 
     SALMON DURIE STAGING       ISS CRITERIA 
I All of the following: 
  Hemoglobin value >10 
g/dL 
  Serum calcium value 
normal or ≤12 mg/dL 
  Bone x-ray, normal bone 
structure (scale 0) or 
solitary bone 
plasmacytoma only 
  Low M-component 
production rate — IgG 
value <5 g/dL; IgA value 
<3 g/dL  
Bence Jones protein <4 g/24 h 
β2-M < 3.5 mg/dL and 
albumin ≥3.5 g/dL 
 
 
 
 
 
 
 
 
 
II  Neither stage I nor stage III Neither stage I nor stage 
III 
III On or more of the following: 
  Hemoglobin value <8.5 
g/dL 
  Serum calcium value >12 
mg/dL 
  Advanced lytic bone 
lesions (scale 3) 
  High M-component 
production rate — IgG 
value >7 g/dL; IgA value 
>5 g/dL — Bence Jones 
protein >12 g/24 h  
 
β2-M ≥  5.5 mg/Dl 
Durie-Salmon sub classifications (either A or B) 
A: Relatively normal renal function (serum creatinine value <2.0 
mg/dL 
B: Abnormal renal function (serum creatinine value ≥2.0 mg/dL  
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FACTORS FAVOURING GOOD PROGNOSIS 
Beta-2 microglobulin 2.5 mg/l* 
C-reactive protein 4.0 mg/dl* 
No -13/13q- chromosome abnormalities 
Plasma cell labeling index less than 1% 
Absence of plasmablastic morphology 
12 months prior treatment 
Chemotherapy sensitive disease 
Any complete remission 
Non IgA isotype (controversial) 
Low Interleukin-6 receptor 
TREATMENT FOR STAGE I MULTIPLE MYELOMA 
 
Patients with stage I or smouldering myeloma do not need 
primary therapy because they can do well with out therapy for 
months to years, before the disease progresses.These candidates 
should be observed every 3-6 months for disease progression. 
 
TREATMENT FOR STAGE II AND III MULTIPLE  
MYELOMA 
 
A .PATIENTS SUITABLE FOR TRANSPLANT 
 
B.PATIENTS NOT SUITABLE FOR TRANSPLANT 
A. PATIENT SUITABLE FOR TRANSPLANT - 
 
1. all newly diagnosed patients and priorly treated patients 
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2 preferably below 65yrs 
 
3 preferably normal renal function 
 
4. good performance status. 
 
 
Exposure to myelotoxic agents (including alkylating agents and 
nitrosoureas) should be limited to avoid compromising stem-
cell reserve prior to stem-cell harvest in patients who may be 
candidates for transplant. 
PRIMARY CONVENTIONAL THERAPY: 
1.Melphalan/prednisone (MP) 
2.Vincristine/doxorubicin/dexamethasone (VAD) 
3.High dose Dexamethasone 
4.Thalidomide/dexamethasone 
5.Liposomal doxorubicin/vincristine/dexamethasone (DVD) 
    Stem cell transplant : following the induction therapy , stem cell 
transplant is performed for the eligible individuals. Autologous 
stem  cell transplant is usually done . Tandem stem cell transplant 
refers to planned second course of high dose therapy and stem cell 
transplant within six months of the first. Allogenic transplants 
have been limited due to lack of donors and increasing morbidity. 
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MAINTAINENECE THERAPY  
Steroids (category 1 for 50 mg prednisone every other day) 
Interferon  (category 2B)  
                  Studies have not clearly proved that maintiance 
therapy reduces disease recurrences.Hence the role of 
dexamethasone or interferon as maintainence therapy in general is 
uncertain.  
High-dose cyclophosphamide 
 SALVAGE THERAPY : 
1.Patients with progressive disease following allogeneic or 
autologous stem cell transplant. 
2.patients with primary progressive disease following initial 
autologous or allogeneic stemcell transplant. 
3.non transplant candidates with progressive or relapsing disease 
after the induction therapy. 
Options available are: 
Repeat primary conventional therapy (if relapse at > 6 mo) 
Cyclophosphamide-VAD 
Thalidomide. 
Bortezomib (category 1) 
Thalidomide/dexamethasone_ 
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Dexamethasone, thalidomide, cisplatin, doxorubicin, 
cyclophosphamide, and  etoposide (DT-PACE) 
Arsenic trioxide in combination with vitamin C (category 2B) 
 
High dose steroids. 
 
 
ADJUNCTIVE THERAPY: 
 
1.Hypercalcemia - Hydration / furosemide, bisphosphonates, steroids and/or  
 
Calcitonin. 
 
2.Hyperviscosity -   Plasmapheresis should be used as adjunctive therapy for  
 
symptomatic hyperviscosity 
 
3.Anemia  - Consider erythropoietin for anemic patients 
 
4.Infection  - Intravenous immunoglobulin therapy should be considered in the 
 
 setting of recurrent lifethreatening infection. Consider pneumovax and 
 
 influenza vaccine. Consider PCP herpes and antifungal prophylaxis if high  
 
dose dexamethasone regimen 
 
5. Renal Dysfunction 
 
A.Maintain hydration to avoid renal failure 
B. Avoid use of NSAIDs 
C.Avoid IV contrast 
6.Plasmapheresis for hyperviscosity. 
7.Consider prophylactic anticoagulation with thalidomide-based therapy 
8.Bisphosphonates 
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All patients with documented bone disease including osteopenia (category 1) 
 
Use of bisphosphonates in smoldering or stage I disease preferrably in the 
 
context of a clinical trial. These patients should have bone survey yearly 
 
Bone densitometry or metabolic studies should be reserved for clinical trial 
 
Monitor for renal dysfunction with chronic use of bisphosphonates 
Monitor for osteonecrosis of the jaw 
9. Radiation Therapy 
Low-dose radiation therapy (10–30 Gy) can be used as palliative treatment for 
uncontrolled pain, for impending pathologic fracture or impending cord 
compression. Radiation doses utilized should not preclude future administration 
of total-body irradiation . Limited involved fields should be used to limit the 
impact of irradiation on stem-cell harvest or impact on potential future 
treatments. 
10. Consider vertebroplasty. 
 
 
 
. 
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AIMS AND OBJECTIVES 
 
     
 
To study the pattern of clinical, pathological ,biochemical and 
radiological presentation of Multiple Myeloma at Madurai Govt 
Rajaji Hospital. 
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MATERIAL AND METHODS 
 
Twenty six patients of multiple myeloma admitted to the 
Oncology department and department of Medicine at Govt Rajaji 
Hospital, Madurai from july 2005 to Oct 2007 were studied. 
An Observational study with regular follow up to assess the 
response to study was designed.  
All the new cases of multiple myeloma admitted to the 
department of medicine and Department of Oncology  Govt Rajaji 
Hospital were included in the study. The diagnosis of multiple 
myeloma was based on the following findings:  
(1) increased numbers of abnormal, atypical, or immature plasma 
cells in the bone marrow or histologic proof of plasmacytoma;  
(2) presence of an M-protein in the serum or urine. 
(3) bone lesions consistent with those of multiple myeloma . 
GRH madurai primarily caters to the rural population of Madurai and 
the surrounding districts. 
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EXCLUSION CRITERIA 
A. plasma cell reactions to connective tissue disorders, liver disease, 
metastatic carcinoma, or chronic infections were excluded.. 
B.Monoclonal gammopathy of undetermined significance (MGUS),  
C.smoldering multiple myeloma,  
D.solitary plasmacytoma,  
E. plasma cell leukemia were also excluded. 
F. Patients with primary amyloidosis (AL) were included only if 
features of multiple myeloma predominated. 
History taking and clinical examination – All the 26 patients were 
subjected to detailed history taking and meticulous clinical 
examination. 
Laboratory work up – Bichemical work up included urine bencejones, 
done with the heat coagulation method, serum albumin, calcium, uric 
acid done using standard biochemical kits.Serum immuno 
electrophoresis was done using the agar gel electrophoretic method. 
Haematological work up – complete hemogram and bone marrow 
aspiration studies were done .They  were analysed by the Pathologist 
at the department of Pathology GRH. Madurai.   
Skeletal survey -  Xray skull PA and lateral view, Xray pelvis PA 
and lateral view, Xray cervical, thoracic, lumbar spine PA and lateral 
view , chest xray PA and lateral view, xray  humerus PA and lateral 
 33
view, Xray hip and femur PA and lateral view was done in all 
patients. Computerised tomographic scan and Magnetic resonance 
imaging was done when xray findings were inconclusive. 
 
TREATMENT AND FOLLOW UP  –  
 All patients were subjected to 12 cycles of cyclophosphamide 
and dexamethasone therapy, and revevaluted at the end of 6 cycles, 9 
cycles and 12 cycles. 
 
All the data was analysed using the epidemiological information 
package 2003 software. 
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RESULTS 
AGE DISTRIBUTION – 
Out of the 26 patients studied 53.8% of patients belonged to 
40-60yr  age group, while 34.6% belonged to 60-80yr age group, only 
11.6% belonged to 20 -40 yr.  The mean age of presentation was 
52.11yr., the median was 55 yrs and the range was 28 – 72. 
 
TABLE 1 DEMOGRAPHIC DATA FOR 26 PTS WITH 
MULTIPLE MYELOMA 
                    AGE            PATIENT DATA 
                 20-40Yr             11.6% 
                40 – 60 Yr             53.8% 
                60 – 80 yrs            34.6% 
               Mean            52.11yrs 
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SEX DISTRIBUTION –  
Males were slightly more affected than females, of the 26 
patients 53.8% were men and 46.2% were women. The sex ratio of 
men to women, was 1.2:1. 
 
TABLE 2 SEX DISTRIBUTIONS IN 26 PTS OF MYELOMA 
SEX PERCENTAGE OF 
PATIENTS 
MALE            53.8% 
FEMALE             46.2% 
 
                                                                  
CLINICAL SYMPTOMATOLOGY 
Backache  was the presenting symptom in 92.3% of patients. 
The mean duration of the symptom was 6.5  months.  
 
COMPLICATIONS – 
1) Infections, mainly lower respiratory tract infection and urinary 
tract infection was present in only 7.6% of patients. 
2) Compressive myelopathy  was present in 15.4% of patients. 
3) Renal failure  was present in 11.5% of patients. 
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TABLE 3 COMPLICATIONS  IN 26 PATIENTS WITH 
MULTIPLE MYELOMA 
1.INFECTIONS               7.6% ( 2/26) 
2.COMPRESSIVE 
MYELOPATHY 
              15.4%( 4/26) 
3.RENAL FAILURE               11.5% (3/26) 
LABORATORY TESTS  
1.Haemoglobin : Anemia (Hb < 12g/dl) is present in all the patients, 
76.9% had a haemoglobin of less than 8.5g/dl. 
 
Table 4 Haemoglobin level  in 26 patients with Multiple Myeloma 
HEMOGLOBIN    g/dl PERCENTAGE OF 
PATIENTS 
<8.5                       76.9% 
>8.5                       23% 
Median – 8.0g/dl , Mean – 7.5g/dl, Range – 5.6 – 11g/dl 
2.Serum calcium : We had zero incidence of hypercalcemia. The 
mean calcium 8.5mg/dl. 
3.Erythrocyte Sedimentation rate : ESR was raised above 50 mm /hr 
in  all the patients the mean ESR being 72.7mm/hr. 
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4.Serum Creatinine :  only 11.5% of patients had a creatinine of more 
than 2mg/dl. 46.2% of patients had creatinine values between 1.3 to 
1.9mg/dl. 
TABLE 4 SERUM CREATININE LEVELS IN 26 PATIENTS 
WITH MYELOMA 
SERUM 
CREATININE 
PERCENTAGE OF 
PATIENTS 
            <1.3mg/dl                      42.3% 
          1.3 – 1.9mg/dl                      46.2% 
               >2.0mg/dl                      11.5% 
 
5..serum albumin – 65.4% of patients had an serum albumin of 
3.0g/dl and less, only 44.6% of patients had a serum albumin greater 
than 3.0g/dl 
TABLE 5 SERUM ALBUMIN IN 26 PATIENTS WITH 
MYELOMA 
               SERUM ALBUMIN PERCENTAGE OF PATIENTS 
                       <3.1g/dl                         65.4% 
                       >3.0g/dl                         44.6% 
Correlation of serum albumin to degree of plasmacytosis: On 
comparing the serum albumin with degree of plasmacytosis, it was 
noted that serum albumin was lower in patients with more than 50% 
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bone  marrow plamacytosis compared with patients with less than 
50% plasmacytosis with a significant p value of 0.031. 
 
TABLE 6 CORRELATION OF BONEMARROW 
PLASMACYTOSIS 
WITH SERUM ALBUMIN 
DEGREE OF 
PLASMACYTOSIS 
MEAN  SERUM ALBUMIN 
                      <50%                      3.2g/dl 
                      >50%                      2.9g/dl 
                                                                           P value – 0.031 
BONE MARROW EXAMINATION – 
Bonemarrow examination revealed 46.1 % of patients had 
plasmacytosis more than 50%. 
TABLE  7 BONE MARROW PLASMA CELLS IN 26 PATIENTS 
OF MYELOMA 
DEGREE OF 
PLASMACYTOSIS 
PERCENTAGE OF PATIENTS 
                 20 – 50%                53.8% 
                 51 – 70%                26.9% 
                     >70%                19.2% 
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MULTIPLE MYELOMA STAGE AT PRESENTATION : 
84.6% OF patients presented in stage IIIA. 
TABLE 8 STAGE OF PRESENTATION OF 26 CASES OF 
MULTIPLE MYELOMA 
STAGE PERCENTAGE OF 
PATIENTS 
                  IIA                   3.9% (1/26) 
                IIIA                   84.6% (22/26) 
                 IIIB                  11.5% (3/26) 
 
RADIOLOGICAL FINDINGS AT PRESENTATION: 
All the 26 patients had lytic lesions, predominantly involving 
skull, vertebrae and pelvis, few patients had involvement of ribs, 
femur and humerus.15.4% had compreesion fractures, 11.5% of 
patients had osteoporosis. 
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TABLE 9 RADIOLOGICAL FINDINGS OF 26 PTS WITH 
MULTIPLE MYELOMA 
RADIOLOGICAL 
ABNORMALITIES 
PERCENTAGE OF 
PATIENTS 
LYTIC LESIONS                      100% 
PATHOLOGICAL FRACTURES                      15.4% (4/26) 
COMPRESSION FRACTURES                      15.4% (4/26) 
 OSTEOPENIA                      11.5%  (4/26) 
OSTEOSCLEROSIS                      0.0% 
 
RESPONSE TO THERAPY – 18 MONTHS FOLLOW UP 
Of the 16 patients who could be followed upto 18 months in the 
period of 2005 -2007, 75% of patients went in for complete remission 
, 18.7% had relapses, 6.2%  had primary progression of the disease 
and succumbed to it.  
TABLE10 STAGE OF THE DISEASE 18 MONTHS FOLLOW UP 
       Disease  status Percentage of patients 
1. complete remission          75%  (12/16) 
2.relapses         18.7% (3/16) 
3.death         6.2% (1/16) 
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DISCUSSION AND COMPARATIVE ANALYSIS 
1.AGE  DISTRIBUTION OF MULTIPLE MYELOMA 
      On comparitve analysis with the mayoclinic proceedings, a 10 
year study of 1027 patients with multiple myeloma, around 70% of 
patients were above 60 years compared to 34.55 of patients in our 
study and the mean age of presentation is 66 years compared to 53yrs 
in our study, which was similar to the twelve year study conducted 
by All India institute of medical sciences, mean age of incidence 
there being 52 years. 
          Observing these results and corroborative findings from the 
AIIMS study, one can conclude that multiple myeloma has an 
younger age predominance in Indian population compared to western 
population. 
TABLE11 COMPARISION OF MEAN AGE OF PRESENTATION 
OF MYELOMA 
                    STUDY        MEAN AGE 
Kyle etal(Mayo) – 10 yr study 2003                66yr 
Gupta etal (AIIMS) – 12 yr study 1995                52yr 
GRH Madurai – 2005-07               53yr 
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The incidence of multiplemyeloma is very low compared to the 
western counter parts, probably we are not genetically predisposed to 
the disease and the environmental factors play a major role, 
especially pesticides, for instance  95% of patients with myeloma at 
madurai GRH were farmers. This is just an hypothesis and further 
molecular and epidemiological studies have to be done to prove or 
disprove it. 
2. SEX DISTRIBUTION OF MULTIPLE MYELOMA 
In all the three studies there was increased incidence of 
myeloma in males compared to females, however the sex ratio was 
lowest in GRH madurai study followed by the Mayoclinic study and 
the highest was in the AIIMS study, with no statistically significant 
difference. 
TABLE 12 COMPARISION OF SEX RATIO IN MULTIPLE 
MYELOMA 
                    Study               Sex ratio M : F 
Kyle etal – 10 yr study 2003                1.4 : 1 
AIIMS – 12 yr study 1995                1.2 : 1 
GRH Madurai – 2005-07               2.2 : 1 
                                                                         P value – 0.0592 
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SYMPTOMATOLOGY- 95% of our patients presented with 
backache as the presenting symptom, the average duration of 6.5 
months. Backache is the most common presenting symptom of 
multiple myeloma, is present for atleast 6 months according to the 
literatures. 
 
SEVERITY OF ANEMIA – on comparing significant anemia < 8g/dl 
was present in only 7% of patients in mayoclinic study compared to 
30% in the AIIMS study and 66.9% in our study. Although anemia is 
an important factor in the salmon durie staging criteria, attributing it 
to the severity of the disease one must give due consideration to the 
higher incidence of iron deficiency anemia and chronic blood loss 
anemia in our population which could be one of the reasons for such 
wide discrepancies between the Indian and western population. 
Comparing to the Atul etal AIIMS study, the incidence of anemia is 
much higher in our study. All our patients are rural population with 
high incidence of iron deficiency anemia. 
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TABLE 13 COMPARISION OF HEMOGLOBIN LEVEL IN 
MULTIPLE MYELOMA 
           STUDY HEMOGLOBIN    <8 g/dl 
Kyle et al –  2003                 7%             
Gupta et al – 1995                 30% 
GRH Madurai – 2005-07                66.9% 
                                                                  P = 0.023 
ERYTHROCYTE SEDIMENTATION RATES –   Multiple 
Myeloma is one of the few disease with a ESR of more than 100 
mm/hr, the mean ESR in our patients was 72m/hr and 100% of 
patients had an ESR above 50mm/hr, on comparing with the 
Mayoclinic proceedings , they had 84.5% of patients with ESR  more 
than 20mm/hr. both the studies substantiates that ESR is elevated in 
majority of cases of multiple myeloma, thus could be used as a 
adjuvant screening marker . 
             
4. SERUM CREATININE –  
     Comparing the incidence of renal failure in patients with multiple 
myeloma, with creatinine of >2mg/dl, there was no statistically 
significant difference between our study and the mayoclinic 
proceedings 2003. 
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TABLE 14 COMPARISION OF SERUM CREATININE LEVEL IN 
MYELOMA 
STUDY SERUM CREATININE >2mg/dl 
Kyle.etal 2003 (Mayo)                     19% 
GRH madurai  2005 -07                    11.5% 
 
5.SERUM ALBUMIN  – The mean serum albumin for our patients 
was 2.9g/dl, on correlating the serum albumin level to the tumour 
burden  reflected by the degree of plasmacytosis, there was a 
statistical difference in the serum albumin level between the two 
groups, ( p =  0.03 ). Several studies have clearly shown low serum 
albumin level as a poor prognostic indicator and correlates with 
severity of the disease.This study also showed that it has a direct 
correlation with the tumour burden.  According to ISS staging we 
take serum albumin of 3.5g/dl as a cut off for stage I multiple 
myeloma. Majority of our patients were in Stage III according to 
Salmon Durie criteria, that could probably explain the serum albumin 
level in patients with plasmacytosis of <50% being 3.2g/dl. Clearly 
although  Serum albumin is influenced by the tumour burden, all the 
factors determining the severity of the disease tend to influence 
serum albumin. 
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TABLE 15 CORRELATION OF BONEMARROW 
PLASMACYTOSIS 
WITH SERUM ALBUMIN 
DEGREE OF 
PLASMACYTOSIS 
MEAN  SERUM 
ALBUMIN 
                      <50%                      3.2g/dl 
                      >50%                      2.9g/dl 
                                                                       
                                                                             P – 0.03                                  
6.BONEMARROW PLASMACYTOSIS  AT PRESENTATION : 
40% of our patients had Bone marrow plasmacytosis of >50% 
as compared to 45% of  patients in the Mayoclinic proceedings 2003. 
There was no statistical difference between the two studies. From 
this we can infer that multiple myeloma usually presents at an 
advanced stage, with more than one third of the patients having an 
plasmacytosis of more than 40%. 
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TABLE16 COMPARISION OF BONEMARROW 
PLASMACYTOSIS IN MYELOMA  
             STUDY DEGREE OF 
PLASMACYTOSIS > 50% 
Kyle etal 2003 (Mayo)                          45% 
GRH MADURAI 2005-07                          40% 
 
7.RADIOLOGIC FINDINGS IN MULTIPLE MYELOMA –  
All our patients had evidence of lytic lesion  in the skeletal 
survey, it was a part of our inclusion criteria. In the Mayoclinical 
proceedings only 76% had lytic lesions, this difference could be 
explained  with the inclusion of  MGUS, smouldering myeloma, non 
secretory myelomas in the study as opposed to only active 
symptomatic myeloma patients in our study. The incidence of 
pathological fractures and compression fractures were similar. 
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TABLE 17 COMPARISION OF RADIOLOGICAL FINDINGS IN 
MYELOMA 
  FINDINGS  Kyle et al GRH Madurai study 
Lytic lesions           76%         100% 
Pathological fractures           26%         15.4% 
Compression 
fractures 
          22%         15.4% 
Osteopenia           23%         11.5% 
 
The difference in the pathological fractures and compression 
fractures in mayoclinic proceedings and our study at GRH Madurai 
was not statistically significant, with a p value of 0.079. The 
incidence of osteosclerosis was very less in both the study, 0.5% in 
mayoclinic proceedings and 0% in our study. 
 
RESPONSE TO THERAPY:   
Only 16 patients could be followed up to 18 months in the 
period of 2 years. All the patients received 12 cycles of 
cyclophosphamide and dexamethasone. Of the 16 patients, 75% had 
complete remission. In Atul et al a study of 44 patients of multiple 
myeloma with 40 month followup , on melphalan and dexamethasone 
therapy, the complete remission rate at 40 months was 26.1%. well 
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since there is a gross difference between the  duration of the study 
and the number of patients studied, there is a higher chance of 
statistical error. Hence further follow up of these patients would be 
needed to compare the actual complete remission rate with 
cyclophosphamide and dexamethasone. In comparision with 
melphalan and dexamethasone. 
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                      LIMITATIONS OF THE STUDY  
1) Urine Bence Jones Proteins was analysed with the routine heat 
coagulation method which is not reliable.. 
2) Beta2microglobulin , LDH, C reactive protein could not be 
done for all the patients due to the lack of availability of the 
facilities at our hospital. 
3) Plasma labeling index could not be caluculated for our patients 
due to lack of facility. 
4) Follow up of the patients was only for 18 months. 
5) 11% of patients were lost for follow up. 
6) Osteoporosis  in the 11.5% of patients was picked up by the 
MRI scan which was not done in all patients, nor the DEXA 
scan was done in all patients, hence the incidence of 
osteoporosis might be incorrect. 
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                                    CONCLUSION  
1) Multiple myeloma presents a decade earlier in Indian 
population compared to the world mean age of presentation. 
2) Backache is the most common presenting symptom, was present 
for minimum of 6.5 months. 
3) The incidence of anemia is comparatively higher in our 
patients.  
4) There is a definite correlation with bone marrow plasmacytosis 
and serum albumin. 
5) Most of our Patients are in stage IIIA at time of diagnosis. 
6) The incidence of renal failure in our patients is comparable to 
the world statistics. 
7) Our patients ’response to alkylating agents and high dose 
dexamethasone therapy is on par with the international 
complete response rate. 
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RESPONSE CRITERIA FOR MULTIPLE MYELOMA 
 
International Myeloma Working Group Uniform Response Criteria 
 
Response Category Response Criteria1 
 
sCR, stringent complete response 
 
CR as defined below plus: 
Normal free light chain (FLC) ratio and absence of clonal cells in bone marrow2 
by immunohistochemistry or immunofluorescence3 
CR, complete response Negative immunofixation on the serum and urine and disappearance of any soft 
tissue plasmacytomas and < 5% plasma cells in bone marrow2 
VGPR, very good partial response 
 
Serum and urine M-protein detectable by immunofixation but not on 
electrophoresis or 90% or greater reduction in serum M-protein plus urine M-
protein level < 100 mg per 24 h 
PR, partial response 
 
>50% reduction of serum M-protein and reduction in 24 h urinary M-protein by 
>90% or to <200 mg per 24 h 
If the serum and urine M-protein are unmeasurable, a > 50% decrease in the 
difference between involved and uninvolved FLC levels is required in place of 
the M-protein criteria 
If serum and urine M-protein are unmeasurable, and serum free light assay is 
also unmeasurable, > 50% reduction in plasma cells is required in place of M-
protein, provided baseline bone marrow plasma cell percentage was > 30% 
In addition to the above listed criteria, if present at baseline, a > 50% reduction 
in the size of soft tissue plasmacytomas is also required 
SD, stable disease 
(not recommended for use as an indicator 
of response; stability of disease is best 
described by providing the time to 
progression estimates) 
Not meeting criteria for CR, VGPR, PR or progressive disease 
 
 
 
 
RELAPSE SUBCATEGORY RELAPSE CRITERIA 
International Myeloma Working Group Uniform Response Criteria 
Progressive disease 1 (To be 
used for calculation of time to 
progression and progression-
free survival and points for all 
patients Including those in 
CR) (includes primary 
progressive disease and 
disease progression on or off 
therapy) 
 
Progressh’e Disease: requires any one or more of the following: 
Increase of >25% from baseline in: 
• Serum M-component and/or (the absolute increase must be > 0.5 g/dL) 
• Urine M-componont and (the absolute increase must be < 200 mg/24 h 
• Only in patients without measurable serum and urine M-proteln levels: the difference between 
involved and uninvolved FLC levels. The absolute Increase must be> 10 mg/dL. 
• Bone marrow plasma cell percentage: the absolute % must be > 1O% 
• Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in 
the size of existing bone lesions or soft tissue plasmacytomas 
• Development of hyporcalcemia (corrected serum calcium > 11.5 mg that can be aftributed 
solely to the plasma cell proliferative disorder 
Clinical relapse1 
 
Clinical relapse requires one or more of: 
Direct indicators of increasing disease and/or end organ dysfunction ICRAB features). It is not 
used in calculation of time to progression or progression-free survival but is listed here as 
something that can be reported optionally or for use in clinical practice 
• Development of new soft tissue plasmacytomas or bone lesions 
• Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is 
defined as a 50% (and at least 1 cm) increase as measured serially by the sum of the products of 
the cross-diameters of the measurable lesion 
• Hypercalcemia (> 11.5 mgldL) 
• Decrease in hemogloblin of > 2 g!dL 
• Rise in serum creatinine by 2 mgldL or more 
Relapse from CR1 
(To be used only if the end 
point studied us DFS disease 
free survival )4 
Any one or more of the following: 
(To be used only it the end 
• Reappearance of serum or urine M-protein by Immunofixation or electrophoresis 
point studied Is DFS 
• Development of >5% plasma cells in the bone marrow3 
Apperance of any other sign of progression (ie, new plasmacytoma , lytic bone lesion, or , 
hypercalcemia)  
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